HSD11B1 and metabolic syndrome: Since HSD11B1 inhibition is now recognized as a promising pathway for pharmacological treatment of obesity, T2DM and MetS, our results might have an importance in future pharmacogenetics studies regarding the clinical testing of genetic variations that could give rise to different responses to HSD11B1 inhibitors.